List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.
Mutation in two copies of the IKBKB gene leads to abnormal function of regulatory T cells, causing psoriatic arthritis.
In this Q&A, Aki Ko, CEO and co-founder of Elixirgen Therapeutics, elucidates how their new mRNA technology could potentially restore muscle function in those suffering from Duchenne muscular dystrophy.
Inhibiting the LDHA and GOT1 enzymes could prevent cancer cells’ ability to produce energy, without affecting healthy cells.
New findings show that age-related MC4R+ cilia shortening causes middle-aged obesity and leptin resistance, which could lead to obesity treatment.
The new findings could lead to a therapeutic target for immune-related disorders, like multiple sclerosis.
Results from an in vivo CRISPR knockout screen, targeting genes involved in autophagy, could lead to new therapies.
Researchers discover that fusion proteins and a gene regulatory protein complex interact through disordered domains.
Researchers have designed the first small molecule drug targeting K-Ras GD12, which could improve pancreatic cancer outcomes.
Researchers find that an overgrowth of nerve cells in the bladder could cause rUTIs, which may offer new approaches to manage symptoms.
Researchers have discovered that higher expression of gigaxonin suppresses aggressive growth of human head and neck cancer cells.
Researchers have identified that AF1q is highly expressed in neuroblastoma, and could be used to destabilise N-Myc.
Future interventions for ischaemic stroke patients should enhance collateral function to reduce brain haemorrhage and mortality.
